TeamDrive
RUS

Our projects

Team Drive is engaged in managing two large active projects under cooperation between the  Russian investment corporation RUSNANO which is currently implementing the national policy on the development of high-tech sectors and Domain Associates LLC., a leading US-based venture capital firm with an exclusive focus on life sciences. In March 2012 the partners announced the signing of an agreement to be subject to investments in innovative medical technologies.

To perform this task a subsidiary RMI Partners, a company specializing in managing pharmaceutical and medical projects, has been established by Team Drive.

RusnanoMedInvest

www.rmi.com.ru

RusnanoMedInvest (a subsidiary of RUSNANO) – was founded in March 2012 and is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology. Initial funding - $ 380 mln.

Read more...


NovaMedica

www.novamedica.com

NovaMedica is a modern Russian pharmaceutical company established in 2012 by leading U.S. venture capital firm Domain Associates LLC and RUSNANO, an investment fund that implements state policy for the development of Russia’s high-technology industries. NovaMedica's strategy is focused on the search, registration and localization in Russia of innovative pharmaceutical products and technologies, as well as the development of the company’s own research and development activities and the establishment of a GMP-compliant pharmaceutical production facility in Russia.

Read more...


RMI Partners

www.rmivc.com

RMI Patners - a pharmaceutical project management company with a focus on investments to out of the box developments in medical, pharmaceutical and biotechnology sectors worldwide. The company’s key mission – to develop and introduce innovative drugs and medical equipment into the market and to create world-class Russian domiciled expertise in Life Sciences venture financing.

Read more...


The Network of Clinics "Doctor Ryadom"

www.drclinics.ru

Doctor Ryadom is a dynamically developed network of private clinics which was created in Moscow in 2014 by Team Drive and a group of private investors within public-private partnership with Moscow City Government.  The first clinic started its work in April 2014 in a new, densely populous district in South-East of Moscow. In less than a year Doctor Ryadom opened in such areas of Moscow 10 modern, well-equipped, multidimensional clinics for adults and children. 

Read more...

Media Center

  • 19 September 2018

    Russia approves new state strategy for pharmaceutical industry

    A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

  • 18 September 2018

    The Ministry of Health of the Russian Federation improves patent protection law

    The Ministry of Health of Russia has published a notification on the development of amendments to Federal Law No. 61 of 12.04.2010 “On circulation of medicinal products”, designed to synchronize it with regulatory acts of the Eurasian Economic Union. The procedure for registration of the medicinal product will be corrected.

  • 17 September 2018

    GlobalData published new report on the Top 25 pharma companies

    The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

  • 14 September 2018

    US scientists conduct clinical trial of influenza vaccine with imiquimod

    A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor College of Medicine in Houston (USA). Investigators are evaluating whether imiquimod cream, which is commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years. 

Read more